The combined databases of the Urological Research Institute (URI, n=2,209) of San Raffaele Hospital and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC, n=2,598) were queried for patients with non-metastatic MIBC treated with RC between January 1990 and September 2017 ( Figure 1 ). The criteria for initial patient selection included: any histology, clinical TanyNanyM0 stage, and radical cystectomy performance with or without perioperative chemotherapy 1 . An external cohort was also analysed including 1,984 pts with UC 97 patients with SCC who had their tumor assessed with an hybrid capture-based comprehensive genomic profiling (CGP) as routine clinical practice. CGP was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP)-accredited laboratory (Foundation Medicine, Inc., Cambridge, MA). The samples were assayed by CGP using adaptor-ligation and hybrid capture performed for all coding exons of from 287 (version 1) to 315 (version 2) cancer related genes plus select introns from 19 (version 1) to 28 (version 2) genes frequently rearranged in cancer. Sequencing of captured libraries was performed using the Illumina HiSeq technology to a mean exon coverage depth of >500X, and resultant sequences were analyzed for all classes of genomic alterations (GA) including short variant (SV) alterations (base substitutions, insertions and deletions), copy number alterations (focal amplifications [<20 Mb], non-focal amplifications [≥20 Mb], and homozygous deletions), and select gene fusions or rearrangements. TMB was determined on 0.8 Mb (version 1) or 1.1 Mb (version 2) of sequenced DNA for each sample based on the number of somatic base substitution or indel alterations per Mb after filtering to remove known functionally oncogenic somatic mutations 2 . Finally, the interim results of the PURE-01 study 3 (NCT02736266) were recently published, reporting a pathologic complete response rate (pT0) of 42% among the first 50 patients enrolled (Necchi A, et al. J Clin Oncol 2018) . Since then, the study was amended to increase the sample size, allow the inclusion of cT4 patients, and allow the inclusion of nonurothelial histologies. Here, we report the interim results of pembrolizumab use in patients with pure or predominant SCC histology.
Analyses on the URI/RISC database were performed by grouping variant histologies into 6 categories, where pure and mixed cases of each histological variant were respectively combined. Furthermore, we analysed data by separating pure from mixed cases of each variant histology. Here, 11 histological subgroups were tested as independent predictors. For example, SCC was analysed combining pure and mixed cases, and also as pure SCC and UC with SCC component, separately. The primary study endpoint was the cancer-specific survival (CSS), which was analysed across all different histological variants and according to treatment delivered. Here, UC was used as reference category while all others histological variants were compared with ( Figure 2 ).
The secondary endpoint was the clinical-to-pathological downstaging, which was defined as a pathologic nodal stage (N stage) that was at least one stage lower than the pre-NAC clinical N stage. When no variation of the N stage occurred, we used the above-mentioned criteria using the tumour stage (pre-NAC cT and pT). Kaplan-Meier method was used for estimation of CSS, both defined as the period of survival from RC. Logistic regression and Cox regression models were used to analyse the effect of NAC, and supportive subgroup analyses were run.
Within the FMI data, hybrid-capture based CGP of 97 patients with squamous-cell carcinoma patients were examined ( Figure 3 ). Tile plot was generated for SCC patients (Figure 4) . Finally, clinical-relevant gene frequency were reported according to UC and SCC histologies with associated p values ( Figure 5 ). All statistical tests were two-sided with a level of significance set at p<0.05. Analyses were performed using the R software environment for statistical computing and graphics.
STATISTICAL ANALYSIS
• SCC was the variant histology exhibited the lowest effect of neoadjuvant chemotherapy in terms of activity and CSS.
• Genomic profiling revealed opportunities for targeted immunotherapy.
• Genomic correlates of SCC chemotherapy resistance warrant further investigation • Finally, data coming from the PURE-01 study show un unprecedented benefit of neoadjuvant immunotherapy on SCC. Clinically relevant alterations occurred in PIK3CA (42.3%), CCND1 (15.5%), PTEN (9.3%), FGFR3 (9.3%), and ERBB2 (6.2%).
CONCLUSIONS STUDY FLOW-CHART
''The most significant differences in the frequency of gene alterations between SCC and UC groups involved CDKN2A, PI3KCA, and NFE2L2, all of which were more frequently altered in SCC'' PURE-01 study: neoadjuvant Pembrolizumab (3 courses of pembrolizumab 200 mg intravenously every 3 weeks, followed by RC) in cT2-3bN0M0 BCa patients with UC predominant histology.
The PURE-01 has been recently amended with the inclusion of divergent histologies, such as SCC (n=12), which represents the focus of the third part of our study TURB and RC specimens were used to analyse biomarkers and match pre and post-therapy results. PD-L1 expression was determined by immunohistochemistry
Within patients with SCC, 4 pT0 (33.3%) and 10 pT≤1 (83.3%) were obtained, and no SCC pts died after a median follow-up of 10.4 months. TURB samples from all patients were retrospectively analysed. Tumors of all pts which underwent IHC demonstrated PD-LI expression.
